Redeye believes the Phase Ib results support plans for developing combination treatments with MIV-81...
The initiation of Asarina Pharma’s phase IIa study in Tourette’s has been postponed until December 2...
Redeye ser positivt på de uppdaterade resultaten i spridd lungcancer, i synnerhet i patienter som in...
Redeye has increased estimates and fair value for Aspire as the company continues to perform stronge...
Redeye re-initiates coverage of Imint with strengthened conviction following a deep dive into its ma...
BankNordik is set to distribute DKK 450m (DKK ~47 per share) in Q4 following the sale of its Danish ...
Shortcut Media Group (”SMG” eller ”bolaget”) har idag den 16 september 2021 kommunicerat ett flertal...
Redeye comments on yesterday’s directed share issue of EUR 4 million.
Strengthens the Spanish position through M&A Adds 3.
Tellusgruppens intäkter fortsätter att öka. Bolaget ökade sina intäkter med cirka 17 procent under d...
(Rättelsen gäller länken som har uppdaterats) Spiffbet rapporterar ett andra kvartal där nettoomsätt...
FDA regards Calliditas amended application as a major amendment very late in the approval process an...
Calliditas meddelade under tisdagskvällen att den amerikanska läkemedelsmyndigheten FDA har skjutit ...
When Biovica announced that the FDA was not yet ready to accept Biovica’s updated application, this ...
Scanfil hosted its first-ever CMD yesterday, during which the company elaborated on customer service...
Sdiptech lifted its M&A-related financial target yesterday evening (14 September), ahead of its CMD.
BoligPortal’s new product offering set to release potential Remains on the lookout to acquire new IT...
Guidance for ‘21 includes pickup in H2, but looks doable Next step for MTHH is to focus on balancing...
Confident message from CEO Supply chain issues expected to be solved by end of 2021 M&A multiples ar...
Redeye views the agreement with Visa as a step forward for the company to reach its goal of being ac...
